Michael Abrams of Numerof & Associates explains the need for the U.S. Food and Drug Administration to move faster on healthcare artificial intelligence governance, and why its drug development ...
In January, the U.S. Food and Drug Administration (FDA) issued its first guidance on the use of artificial intelligence (AI)[1] models in drug development and in regulatory submissions titled, ...
A recent article[1] authored by Haider J. Warraich, MD[2]; Troy Tazbaz[3]; and Robert M. Califf[4], MD in the Journal of the American Medical Association, reviews the history of artificial ...
After its founding in 1976, scientists at Genentech worked methodically toward the development of its first biotechnology product. It was nearly a decade later that the FDA approved Protropin, a ...
At the heart of every biological process, from the replication of cells to the functioning of the human brain, lies the intricate world of proteins. Understanding the structure of these molecules, ...
The antibody drug market value is expected to reach $445 billion in the next five years, with over 160 antibodies currently licensed globally for a wide breadth of conditions, including cancer, ...
Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...
Genesis’ proprietary foundation model – Pearl – outperforms frontier models, including AlphaFold 3, on key benchmarks that predict utility in real-world drug discovery Pearl’s performance improved ...
CAMBRIDGE, Mass., Dec. 11, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback